Technology evaluation: Chrysalin (Orthologic).
OrthoLogic (formerly Chrysalis) is developing Chrysalin, a synthetic 23-amino acid peptide that mimics a portion of human thrombin. The compound is in phase II clinical trials for the potential treatment of diabetic foot ulcers and phase III trials for cartilage repair and bone fractures.
University of Southern California, School of Medicine, 1321 North Mission Road, Los Angeles, CA 90033-1020, USA. krodgers@usc.edu
Kathleen E
KE
Rodgers
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D017719:Diabetic Foot / Q000188:drug therapy*; D006801:Humans; D010446:Peptide Fragments / Q000737:chemistry / Q000627:therapeutic use*; D010455:Peptides / Q000737:chemistry / Q000627:therapeutic use*; D013917:Thrombin / Q000737:chemistry / Q000627:therapeutic use*
D010446:Peptide Fragments; D010455:Peptides; C412222:rusalatide acetate; D013917:Thrombin